Discovery of a human monoclonal antibody that cross-neutralizes venom phospholipase A2s from three different snake genera
Sørensen, C. V., Almeida, J. R., Bohn, M.-F., Torre, E. R. d., Schoffelen, S., Voldborg, B. G., Ljungars, A., Vaiyapuri, S.
It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing. To link to this item DOI: 10.1016/j.toxicon.2023.107307 Abstract/SummaryDespite the considerable global impact of snakebite envenoming, available treatments remain suboptimal. Here, we report the discovery of a broadly-neutralizing human monoclonal antibody, using a phage display-based cross-panning strategy, capable of reducing the cytotoxic effects (using a mouse myoblast cell line that may demonstrate the impact of venoms on skeletal muscle) of venom phospholipase A2s from three different snake genera from different continents. This highlights the potential of utilizing monoclonal antibodies to potentially compose more effective, safer, and globally accessible polyvalent antivenoms that hopefully can be widely applicable for snakebite envenomings.
Download Statistics DownloadsDownloads per month over past year Altmetric Deposit Details University Staff: Request a correction | Centaur Editors: Update this record |
Lists
Lists
![[img]](/style/images/fileicons/text.png)